Collins Helen Louise
Insider CIK 1701247 · FPRX SVP and Chief Medical Officer · KURA Director · ELVN Chief Medical Officer · IOBT Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-10-19 | 2026-10-21 | 5,000 | — | $0 | 101,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-10-19 | 2026-10-21 | 5,000 | $38.47 | $192.3K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-10-19 | 2026-10-21 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-09-17 | 2026-09-21 | 5,000 | — | $0 | 106,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-09-17 | 2026-09-21 | 240 | $51.48 | $12.4K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-09-17 | 2026-09-21 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-09-17 | 2026-09-21 | 2,916 | $50.03 | $145.9K | 27,084 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-09-17 | 2026-09-21 | 1,844 | $50.71 | $93.5K | 25,240 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-09-17 | 2026-09-21 | 5,000 | — | $0 | 106,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-09-17 | 2026-09-21 | 240 | $51.48 | $12.4K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-09-17 | 2026-09-21 | 1,844 | $50.71 | $93.5K | 25,240 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-09-17 | 2026-09-21 | 2,916 | $50.03 | $145.9K | 27,084 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-09-17 | 2026-09-21 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-08-17 | 2026-08-19 | 5,000 | — | $0 | 111,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-08-17 | 2026-08-19 | 1,100 | $59.35 | $65.3K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-08-17 | 2026-08-19 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-08-17 | 2026-08-19 | 3,900 | $58.37 | $227.6K | 26,100 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-08-17 | 2026-08-19 | 5,000 | — | $0 | 111,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-08-17 | 2026-08-19 | 1,100 | $59.35 | $65.3K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-08-17 | 2026-08-19 | 3,900 | $58.37 | $227.6K | 26,100 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-08-17 | 2026-08-19 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-07-17 | 2026-07-21 | 5,000 | — | $0 | 116,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-07-17 | 2026-07-21 | 459 | $51.55 | $23.7K | 29,310 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-07-17 | 2026-07-21 | 231 | $50.05 | $11.6K | 29,769 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-07-17 | 2026-07-21 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-07-17 | 2026-07-21 | 63 | $53.92 | $3.4K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-07-17 | 2026-07-21 | 2,184 | $53.42 | $116.7K | 25,063 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-07-17 | 2026-07-21 | 2,063 | $52.39 | $108.1K | 27,247 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-06-17 | 2026-06-22 | 5,000 | — | $0 | 121,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-06-17 | 2026-06-22 | 1,133 | $44.74 | $50.7K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-06-17 | 2026-06-22 | 2,599 | $43.87 | $114.0K | 26,133 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-06-17 | 2026-06-22 | 1,268 | $42.83 | $54.3K | 28,732 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-06-17 | 2026-06-22 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| KURA Kura Oncology, Inc. | A Award deriv | 2026-06-04 | 2026-06-04 | 35,000 | — | $0 | 35,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-05-18 | 2026-05-20 | 5,000 | — | $0 | 126,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-05-18 | 2026-05-20 | 223 | $41.21 | $9.2K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-05-18 | 2026-05-20 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-05-18 | 2026-05-20 | 3,475 | $39.53 | $137.4K | 26,525 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-05-18 | 2026-05-20 | 1,302 | $40.25 | $52.4K | 25,223 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-04-17 | 2026-04-21 | 5,000 | — | $0 | 131,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-04-17 | 2026-04-21 | 2,419 | $47.39 | $114.6K | 27,441 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-04-17 | 2026-04-21 | 140 | $45.81 | $6.4K | 29,860 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-04-17 | 2026-04-21 | 2,441 | $48.06 | $117.3K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-04-17 | 2026-04-21 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-03-25 | 2026-03-27 | 40,000 | — | $0 | 136,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-03-25 | 2026-03-27 | 40,000 | $35.10 | $1.40M | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-03-25 | 2026-03-27 | 40,000 | $2.48 | $99.2K | 65,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-03-17 | 2026-03-19 | 5,000 | — | $0 | 176,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-03-17 | 2026-03-19 | 5,000 | $2.48 | $12.4K | 30,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-03-17 | 2026-03-19 | 5,000 | $27.76 | $138.8K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-03-10 | 2026-03-11 | 10,129 | — | $0 | 181,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-03-10 | 2026-03-11 | 10,129 | $2.48 | $25.1K | 35,129 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-03-10 | 2026-03-11 | 10,129 | $30.19 | $305.8K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-03-09 | 2026-03-11 | 29,871 | — | $0 | 191,397 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-03-09 | 2026-03-11 | 29,871 | $2.48 | $74.1K | 54,871 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-03-09 | 2026-03-11 | 29,871 | $30.02 | $896.7K | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2026-02-17 | 2026-02-19 | 45,000 | — | $0 | 221,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2026-02-17 | 2026-02-19 | 45,000 | $2.48 | $111.6K | 70,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2026-02-17 | 2026-02-19 | 45,000 | $26.17 | $1.18M | 25,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2026-02-12 | 2026-02-17 | 150,000 | — | $0 | 150,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award | 2026-02-12 | 2026-02-17 | 25,000 | — | $0 | 25,000 | SEC↗ |
| KURA Kura Oncology, Inc. | A Award deriv | 2025-06-05 | 2025-06-06 | 28,500 | — | $0 | 28,500 | SEC↗ |
| IOBT IO Biotech, Inc. | A Award deriv | 2025-06-05 | 2025-06-06 | 35,144 | — | $0 | 35,144 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2025-02-06 | 2025-02-10 | 171,000 | — | $0 | 171,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-10-18 | 2024-10-22 | 816 | — | $0 | 266,268 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-10-18 | 2024-10-22 | 816 | $2.48 | $2.0K | 816 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-10-18 | 2024-10-22 | 816 | $30.00 | $24.5K | 0 | SEC↗ |
| IOBT IO Biotech, Inc. | A Award deriv | 2024-06-06 | 2024-06-07 | 45,642 | — | $0 | 45,642 | SEC↗ |
| KURA Kura Oncology, Inc. | A Award deriv | 2024-06-05 | 2024-06-07 | 26,000 | — | $0 | 26,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise deriv | 2024-04-11 | 2024-04-15 | 20,000 | — | $0 | 267,084 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | S Sale | 2024-04-11 | 2024-04-15 | 20,000 | $25.07 | $501.4K | 0 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | M Exercise | 2024-04-11 | 2024-04-15 | 20,000 | $2.48 | $49.6K | 20,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2024-02-13 | 2024-02-15 | 185,000 | — | $0 | 185,000 | SEC↗ |
| IOBT IO Biotech, Inc. | A Award deriv | 2023-11-15 | 2023-11-17 | 64,238 | — | $0 | 64,238 | SEC↗ |
| KURA Kura Oncology, Inc. | A Award deriv | 2023-05-31 | 2023-06-02 | 26,000 | — | $0 | 26,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2023-04-04 | 2023-04-06 | 206,000 | — | $0 | 206,000 | SEC↗ |
| ELVN Enliven Therapeutics, Inc. | A Award deriv | 2023-02-23 | 2023-02-27 | 287,084 | — | $0 | 287,084 | SEC↗ |
| KURA Kura Oncology, Inc. | A Award deriv | 2022-06-21 | 2022-06-23 | 23,000 | — | $0 | 23,000 | SEC↗ |
| KURA Kura Oncology, Inc. | A Award deriv | 2021-07-28 | 2021-07-29 | 46,000 | — | $0 | 46,000 | SEC↗ |
| KURA Kura Oncology, Inc. | A Award deriv | 2021-07-28 | 2021-07-29 | 19,166 | — | $0 | 19,166 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | D To issuer deriv | 2021-04-16 | 2021-04-19 | 60,000 | — | $0 | 0 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | D To issuer deriv | 2021-04-16 | 2021-04-19 | 58,000 | — | $0 | 0 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | D To issuer deriv | 2021-04-16 | 2021-04-19 | 50,000 | — | $0 | 0 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | D To issuer deriv | 2021-04-16 | 2021-04-19 | 20,000 | — | $0 | 0 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | D To issuer deriv | 2021-04-16 | 2021-04-19 | 90,000 | — | $0 | 0 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | D To issuer deriv | 2021-04-16 | 2021-04-19 | 90,000 | — | $0 | 0 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | D To issuer | 2021-04-16 | 2021-04-19 | 135,547 | $38.00 | $5.15M | 0 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | A Award | 2021-04-16 | 2021-04-19 | 66,000 | — | $0 | 135,547 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | G Gift | 2021-03-31 | 2021-04-19 | 8,085 | — | $0 | 69,547 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2021-02-26 | 2021-03-02 | 1,158 | $22.23 | $25.7K | 77,632 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2021-02-25 | 2021-02-26 | 1,653 | $23.08 | $38.2K | 78,790 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2021-02-24 | 2021-02-26 | 5,091 | $25.71 | $130.9K | 80,443 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | M Exercise deriv | 2020-12-11 | 2020-12-15 | 22,000 | — | $0 | 0 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2020-12-11 | 2020-12-15 | 11,583 | $16.14 | $186.9K | 85,534 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | M Exercise | 2020-12-11 | 2020-12-15 | 22,000 | — | $0 | 97,117 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | M Exercise deriv | 2020-11-11 | 2020-11-13 | 22,000 | — | $0 | 22,000 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | M Exercise | 2020-11-11 | 2020-11-13 | 22,000 | — | $0 | 86,156 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2020-11-11 | 2020-11-13 | 11,039 | $18.00 | $198.7K | 75,117 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2020-08-20 | 2020-08-24 | 827 | $4.69 | $3.9K | 64,156 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2020-03-20 | 2020-03-23 | 827 | $2.30 | $1.9K | 64,983 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2020-02-26 | 2020-02-26 | 1,281 | $4.83 | $6.2K | 65,810 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2020-02-25 | 2020-02-26 | 1,862 | $4.87 | $9.1K | 67,091 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | A Award deriv | 2020-02-24 | 2020-02-26 | 90,000 | — | $0 | 90,000 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | A Award deriv | 2020-02-24 | 2020-02-26 | 90,000 | — | $0 | 90,000 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | A Award | 2020-02-24 | 2020-02-26 | 15,000 | — | $0 | 68,953 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | A Award | 2020-02-24 | 2020-02-26 | 15,000 | — | $0 | 53,953 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2020-02-05 | 2020-02-06 | 5,345 | $5.13 | $27.4K | 38,953 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | F Tax w/h | 2019-09-01 | 2019-09-04 | 496 | $5.43 | $2.7K | 44,298 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | A Award deriv | 2019-08-20 | 2019-08-22 | 20,000 | — | $0 | 20,000 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS, I | A Award | 2019-08-20 | 2019-08-22 | 5,000 | — | $0 | 44,794 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | A Award deriv | 2019-06-24 | 2019-06-26 | 44,000 | — | $0 | 44,000 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | F Tax w/h | 2019-02-26 | 2019-02-27 | 1,177 | $11.95 | $14.1K | 39,794 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | A Award deriv | 2019-02-25 | 2019-02-27 | 58,000 | — | $0 | 58,000 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | A Award | 2019-02-25 | 2019-02-27 | 10,000 | — | $0 | 40,971 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | F Tax w/h | 2019-02-05 | 2019-02-07 | 3,196 | $11.43 | $36.5K | 30,971 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | A Award | 2018-09-28 | 2018-10-02 | 3,844 | — | $0 | 36,073 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | F Tax w/h | 2018-09-28 | 2018-10-02 | 1,906 | $13.92 | $26.5K | 34,167 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | F Tax w/h | 2018-09-01 | 2018-09-05 | 496 | $14.00 | $6.9K | 32,229 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | F Tax w/h | 2018-06-23 | 2018-06-26 | 1,240 | $17.38 | $21.6K | 32,725 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | F Tax w/h | 2018-03-20 | 2018-03-22 | 827 | $16.26 | $13.4K | 33,965 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | A Award deriv | 2018-02-26 | 2018-02-28 | 50,000 | — | $0 | 50,000 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | A Award | 2018-02-26 | 2018-02-28 | 7,000 | — | $0 | 34,792 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | F Tax w/h | 2018-02-05 | 2018-02-07 | 1,048 | $18.42 | $19.3K | 23,732 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | F Tax w/h | 2017-09-01 | 2017-09-06 | 376 | $34.34 | $12.9K | 24,780 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | F Tax w/h | 2017-06-23 | 2018-02-28 | 940 | $31.24 | $29.4K | 27,792 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | A Award | 2017-04-24 | 2017-04-26 | 1,250 | — | $0 | 25,156 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | A Award deriv | 2017-03-20 | 2017-03-22 | 22,500 | — | $0 | 91,500 | SEC↗ |
| FPRX FIVE PRIME THERAPEUTICS IN | A Award | 2017-03-20 | 2017-03-22 | 3,750 | — | $0 | 23,906 | SEC↗ |